Carlyle Group Inc. acquired a new position in shares of Adicet Bio, Inc. (NASDAQ:ACET – Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,115,385 shares of the company’s stock, valued at approximately $12,163,000. Adicet Bio comprises […]
Theseus Pharmaceuticals, Inc. (NASDAQ:THRX – Get Free Report) Director Carl L. Gordon bought 479,932 shares of the company’s stock in a transaction on Monday, July 17th. The shares were bought at an average price of $3.05 per share, for a total transaction of $1,463,792.60. Following the completion of the acquisition, the director now directly owns […]
A number of research firms have changed their ratings and price targets for Adicet Bio (NASDAQ: ACET): 6/27/2023 – Adicet Bio was downgraded by analysts at Guggenheim from a “buy” rating to a “neutral” rating. 6/27/2023 – Adicet Bio was downgraded by analysts at JMP Securities from an “outperform” rating to a “market perform” rating. […]
Kinnate Biopharma Inc. (NASDAQ:KNTE – Free Report) saw a large growth in short interest in the month of June. As of June 15th, there was short interest totalling 2,170,000 shares, a growth of 29.9% from the May 31st total of 1,670,000 shares. Based on an average daily trading volume, of 541,200 shares, the short-interest ratio […]
Adicet Bio (NASDAQ:ACET – Free Report) had its target price cut by BTIG Research from $34.00 to $20.00 in a research note released on Tuesday morning, The Fly reports. A number of other equities analysts also recently weighed in on the stock. JPMorgan Chase & Co. downgraded shares of Adicet Bio from an overweight rating […]